ArticleJournal of gastroenterology2026
Volatomics-based biomarkers for non-invasive diagnosis and monitoring of inflammatory bowel disease.
Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Letter to the Editor to "Volatomics-based biomarkers for non-invasive diagnosis and monitoring of inflammatory bowel disease".Journal of gastroenterology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
backgroundInflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic disorder that markedly impairs quality of life. Current diagnostic and monitoring tools rely on invasive procedures such as endoscopy, which are costly and burdensome. Volatile organic compounds (VOCs) in breath and feces, reflecting host-microbiota metabolism, have emerged as promising non-invasive biomarkers, but their clinical utility remains underexplored.This study aimed to identify breath- and feces-derived VOCs as novel biomarkers for IBD and to establish artificial intelligence (AI)-based predictive models for non-invasive diagnosis and disease activity monitoring. The relationship between VOC alterations and gut microbiota dysbiosis was also investigated.
methodsA total of 279 participants (131 IBD patients, 148 healthy controls) were enrolled. VOCs from breath and fecal samples were analyzed using gas chromatography-ion mobility spectrometry (GC-IMS). AI-based machine learning models were developed for diagnosis and monitoring. Furthermore, the differences in breath VOCs identified in human cohorts were validated in a DSS-induced colitis mouse model (2% DSS for 7 days). In a subset of 62 individuals, 16S rDNA sequencing characterized gut microbiota composition and its correlation with VOCs.
resultsDistinct VOC profiles were identified in IBD. Ethyl sulfide and furfural were elevated in breath samples, while hexanoic acid, pentanoic acid, thiophene, and ethyl acetate were reduced. In fecal samples, dimethyl trisulfide increased, whereas several short-chain fatty acids(SCFAs) and alcohols decreased. The diagnostic model achieved an AUC of 0.92 (sensitivity 96%, specificity 71%), and the monitoring model an AUC of 0.88, both outperforming C-reactive protein and fecal calprotectin. Validation in a DSS-induced colitis model confirmed eight discriminatory VOCs, characterized by depleted SCFA-related VOCs and elevated sulfide VOCs, underscoring their robust correlation with the development and severity of intestinal inflammation. IBD patients showed reduced microbial diversity and depletion of short-chain fatty acid-producing bacteria, closely correlated with altered VOC profiles.
conclusionsThis study demonstrates that integrating volatomics with AI-based modeling enables accurate, non-invasive diagnosis and monitoring of IBD. The cross-species consistency observed in our human cohorts and DSS-induced colitis mice confirms the reliability of specific VOCs as conserved inflammatory biomarkers. These findings, coupled with VOC-microbiota associations, offer profound mechanistic insights and a promising platform for biomarker-guided precision care.
trial registrationChiCTR, ChiCTR2300073475. Registered 12 July 2023-Prospectively registered, https://www.chictr.org.cn/bin/project/edit?pid=201603 .
Indexed as
Identifiers
41957107What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.